肺高级别神经内分泌癌中PD-L1表达与肿瘤浸润免疫细胞及突变负荷的关联
该研究在192例肺大细胞神经内分泌癌(LCNEC)和小细胞肺癌(SCLC)患者中评估PD-L1在肿瘤细胞(TC)和肿瘤浸润免疫细胞(IC)的表达,并分析其与IC浸润、PTEN缺失及突变负荷的关系。结果显示PD-L1在TC的表达率为15.1%,IC浸润和IC上PD-L1表达率分别为34.4%和31.3%,且IC浸润及IC PD-L1表达与LCNEC和高非同义突变负荷相关。IC浸润及IC PD-L1阳性患者无进展生存期更优。
要点
- 肺高级别神经内分泌癌中PD-L1在TC的表达率为15.1%。
- IC浸润和IC上PD-L1表达率分别为34.4%和31.3%。
- IC浸润及IC PD-L1阳性与更优的无进展生存期相关。
核心结论
- PD-1/PD-L1通路在肺高级别神经内分泌癌微环境中被激活,并与较高突变负荷相关。
研究设计与样本
- 回顾性分析192例肺高级别神经内分泌癌患者,包括LCNEC 72例和SCLC 120例。
- 采用免疫组化(IHC)评估TC和IC上PD-L1表达及PTEN表达状态。
- 使用Ion AmpliSeq Comprehensive Cancer Panel检测409个癌症相关基因编码外显子突变。
主要发现
- PD-L1在TC的表达率为15.1%(29/192)。
- IC浸润率为34.4%(66/192),IC上PD-L1表达率为31.3%(60/192)。
- IC浸润和IC上PD-L1表达与LCNEC相关性更强(57.6% vs 23.3%,p<0.01;45.8% vs 22.5%,p<0.01)。
- PTEN缺失率为9.5%(18/189),与PD-L1表达无相关性。
关键数值与推荐
- PD-L1表达评分标准:TC0/IC0为<1%,TC1/IC1为≥1%且<10%,TC2/IC2为≥10%且<50%,TC3/IC3为≥50%。
- PTEN IHC评分分为表达缺失或保留。
临床怎么用
- 肺高级别神经内分泌癌患者中PD-L1在IC的表达与LCNEC亚型及高突变负荷相关,可能提示免疫微环境活跃。
- IC浸润及IC上PD-L1表达阳性与更优的无进展生存期相关,或可作为预后参考指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The immune microenvironment of high-grade neuroendocrine carcinoma of the lung, including programmed death ligand 1 (PD-L1) expression, has not been well characterized. METHODS: On the basis of immunohistochemistry (IHC) results, PD-L1 expression on tumor cells (TCs) and tumor-infiltrating immune cells (ICs) was scored as follows: TC0 and IC0 were defined as PD-L1 expression less than 1%, TC1 and IC1 as at least 1% but less than 10%, TC2 and IC2 as 10% or more but less than 50%, and TC3 and IC3 as 50% or more. Phosphatase and tensin homolog (PTEN) IHC was scored as either lost or retained expression. The Ion AmpliSeq Comprehensive Cancer Panel (ThermoFisher Scientific, Waltham, MA) was used to identify mutations in all coding exons of 409 cancer-related genes. RESULTS: A total of 192 patients with large cell neuroendocrine carcinoma (LCNEC) (n = 72) and SCLC (n = 120) were studied. The prevalence of PD-L1 expression on TCs was 15.1% (29 of 192). IC infiltration and PD-L1 expression on ICs were observed in 34.4% of patients (66 of 192) and 31.3% of patients (60 of 192), respectively. The prevalence of IC infiltration and PD-L1 expression on IC were more strongly correlated with LCNEC than with SCLC (57.6% versus 23.3%, p < 0.01; 45.8% versus 22.5%, p < 0.01) and high nonsynonymous mutations (p = 0.05 and .04). PTEN loss was found in 9.5% of patients (18 of 189) and showed no correlation with PD-L1 expression. Progression-free survival was better in patients with IC infiltration than in those without IC infiltration (median 11.3 versus 6.8 months [p < 0.01]) and in patients with PD-L1 expression of IC1/2/3 than in those with expression of IC0 (median 11.3 versus 7.0 months [p = 0.03]). CONCLUSION: These findings suggest that the PD-1/PD-L1 pathway is activated in the microenvironment of pulmonary high-grade neuroendocrine carcinoma and correlated with a higher mutation burden.
引用
- Kim HS, Lee JH, Nam SJ, et al. Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung. J Thorac Oncol. 2018. PMID: 29378266. doi:10.1016/j.jtho.2018.01.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。